Mr. Patrick joined C3J as its President and CEO in November 2010. Prior to joining C3J, Todd served as President and Chief Operating Officer and joined the Board of Directors of ID Biomedical Corporation after the Company elected in 1998 to exit its core diagnostic business to focus on vaccines. Todd started ID Biomedical’s vaccine subsidiary in 1994. In September 2005, GlaxoSmithKline purchased ID Biomedical for approximately $1.5 billion plus the assumption of $200 million in debt. To date, the GSK/IDB merger is the second largest “pure play” enterprise value M&A transaction in the history of the vaccine industry. After retiring from ID Biomedical, Todd and a group of investors raised approximately $100 million for a portfolio of small medical companies. He was a director of each of these companies and also acted as a consultant for these and other biotech companies prior to ending his retirement to join C3J. Before he joined ID Biomedical, Todd was appointed the first ever Director of the Office of Intellectual Property Administration at UCLA, helping the organization start its IP program in 1989. Todd is the past Chairman of the Board of Trustees for the Seattle Biomedical Research Institute, a 400 person, non-profit global health organization focused on creating new drugs and vaccines to treat infectious diseases in the developing world. He is a past trustee of a variety of organizations in the Pacific Northwest, including the Washington Biotechnology and Biomedical Association (WBBA), and the WSU Research Foundation. He is on the Board of Directors of CRH Medical Corporation (NASDAQ listed) and privately held Vaxent Vaccines. Todd received his BA from the University of Washington and an MBA from Washington State University.
Dr. Varnum is a biotech veteran with more than twenty years of experience. He began his career with Amgen, and spent more than 18 years at the biotech pioneer as the company grew from a start-up to the largest and most successful biotechnology company. Brian worked in multiple roles, making contributions from discovery research through product launch with a significant focus on bringing new molecules out of the lab and into the clinic. After this experience, Brian joined startups favoring the dynamic entrepreneurial environment. In the 3+ years since joining C3J, he has contributed to the mechanistic understanding of the lead molecule, advanced formulation development for oral and intestinal delivery, and shaped clinical development and pipeline expansion. Brian obtained his Ph.D. from UCLA studying oncogenes, and his drug development research experience includes hematopoietic growth factor discovery, oncology, auto-immune/inflammatory disorders, personalized medicine in IBD and infectious diseases.
Mr. Morris leads the production, quality, facilities, and clinical operations areas for the C3J organization. Prior to joining C3J, Mr. Morris was the Chief Operating Officer at Response Biomedical in Vancouver, Canada. While at Response Biomedical, Mr. Morris directed the expansion of manufacturing facilities and scale-up of in-vitro diagnostic products. Prior to his tenure at Response, Mr. Morris was responsible for all manufacturing and quality control activities for ID Biomedical Corporation until its acquisition by GlaxoSmithKline (GSK). Mr. Morris was then responsible for all North American Operations which included influenza vaccine production for GSK. Mr. Morris started his career at Syntex Corporation in Palo Alto, where he spent 21 years in increasingly responsible positions, ultimately becoming the Director of Pharmaceutical Manufacturing. Mr. Morris earned his BA in Management from Saint Mary’s College in Moraga, California.
Mr. Goesling has over 30 years of financial and accounting experience with rapidly-growing, technology-based companies deploying new and disruptive technologies. Most recently, Dave has been a consultant for biotechnology and other ventures. Prior to that, Dave was the CFO for RF Surgical Systems, a venture capital backed medical device company that developed and sold the leading system to eliminate retained surgical items, a costly medical error that can occur during surgery. Prior to joining RF Surgical, Dave held finance and accounting positions with increasing levels of responsibility in the telecom industry. He began his career in the auditing group at Deloitte & Touche. Dave currently serves on the Board of Trustees and Finance Committee of the Center for Infectious Disease Research in Seattle, WA. Dave earned a BA in Business Administration – Accounting Concentration from the University of Washington, an MBA degree from the University of Chicago, and achieved a Certified Public Accountant designation.
Dr. Wenyuan Shi serves as Chief Executive Officer and Chief Scientific Officer of the Forsyth Insitute, an independent not-for-profit research organization, located in Cambridge, MA. Forsyth is the only independent research institute in America specializing in oral health and its impact on overall wellness. Previously, Dr. Shi was Chairman and Professor of Oral Biology at the UCLA School of Dentistry and a Professor of Microbiology at the UCLA School of Medicine. Dr. Shi has been using multidisciplinary approaches to develop the next generation of diagnostic and therapeutic tools against oral microbial infections, including peptide-based targeted antimicrobial therapeutics and instant chairside detection of oral pathogens. These translational research efforts have resulted in novel technologies that are licensed and developed by major pharmaceutical, dental and biotech companies, including C3J Therapeutics, Inc. Dr. Shi obtained his BS degree from Fudan University in Shanghai in 1984, acquired his Doctoral degree from the University of Wisconsin-Madison in 1991, and fulfilled his postdoctoral training at the University of California Berkeley from 1992-1995. He is the co-author of over 200 scientific articles and is credited as co-inventor of 45 patents.